G1 Therapeutics (GTHX) Stock Rating Upgraded by BidaskClub

BidaskClub upgraded shares of G1 Therapeutics (NASDAQ:GTHX) from a sell rating to a hold rating in a research note published on Saturday.

Other analysts also recently issued research reports about the stock. Cowen reissued a buy rating on shares of G1 Therapeutics in a research report on Thursday, August 9th. Zacks Investment Research downgraded shares of G1 Therapeutics from a hold rating to a sell rating in a research report on Wednesday, July 11th. JPMorgan Chase & Co. boosted their target price on shares of G1 Therapeutics from $58.00 to $63.00 and gave the stock an overweight rating in a research report on Friday, August 10th. BTIG Research began coverage on shares of G1 Therapeutics in a research report on Monday, September 10th. They set a buy rating and a $80.00 target price on the stock. Finally, Needham & Company LLC boosted their target price on shares of G1 Therapeutics to $76.00 and gave the stock a buy rating in a research report on Tuesday, September 18th. Two equities research analysts have rated the stock with a hold rating and six have issued a buy rating to the company’s stock. The stock currently has a consensus rating of Buy and an average target price of $74.50.

NASDAQ GTHX opened at $42.94 on Friday. The company has a market cap of $1.40 billion, a P/E ratio of -12.03 and a beta of 1.16. G1 Therapeutics has a 52 week low of $18.03 and a 52 week high of $69.57.

G1 Therapeutics (NASDAQ:GTHX) last posted its quarterly earnings data on Wednesday, August 8th. The company reported ($0.64) EPS for the quarter, topping the consensus estimate of ($0.65) by $0.01. On average, analysts forecast that G1 Therapeutics will post -2.64 earnings per share for the current year.

In other news, insider Mark A. Velleca sold 5,000 shares of the company’s stock in a transaction on Monday, October 15th. The shares were sold at an average price of $41.53, for a total value of $207,650.00. The transaction was disclosed in a filing with the SEC, which can be accessed through the SEC website. Also, Director Seth Rudnick sold 10,000 shares of the company’s stock in a transaction on Tuesday, September 4th. The shares were sold at an average price of $59.95, for a total transaction of $599,500.00. The disclosure for this sale can be found here. In the last three months, insiders have sold 52,314 shares of company stock worth $2,891,492. 15.92% of the stock is owned by insiders.

Hedge funds have recently added to or reduced their stakes in the company. Cubist Systematic Strategies LLC boosted its holdings in shares of G1 Therapeutics by 484.5% in the 1st quarter. Cubist Systematic Strategies LLC now owns 2,794 shares of the company’s stock valued at $104,000 after acquiring an additional 2,316 shares during the last quarter. BNP Paribas Arbitrage SA boosted its holdings in shares of G1 Therapeutics by 58.4% in the 1st quarter. BNP Paribas Arbitrage SA now owns 2,835 shares of the company’s stock valued at $105,000 after acquiring an additional 1,045 shares during the last quarter. Great West Life Assurance Co. Can boosted its holdings in shares of G1 Therapeutics by 148.3% in the 2nd quarter. Great West Life Assurance Co. Can now owns 2,612 shares of the company’s stock valued at $113,000 after acquiring an additional 1,560 shares during the last quarter. Ladenburg Thalmann Financial Services Inc. boosted its holdings in shares of G1 Therapeutics by 44.4% in the 1st quarter. Ladenburg Thalmann Financial Services Inc. now owns 3,900 shares of the company’s stock valued at $144,000 after acquiring an additional 1,200 shares during the last quarter. Finally, Strs Ohio boosted its holdings in shares of G1 Therapeutics by 78.3% in the 2nd quarter. Strs Ohio now owns 4,100 shares of the company’s stock valued at $178,000 after acquiring an additional 1,800 shares during the last quarter. 69.09% of the stock is currently owned by institutional investors and hedge funds.

About G1 Therapeutics

G1 Therapeutics, Inc, a clinical-stage biopharmaceutical company, focuses on the discovery, development, and commercialization of novel small molecule therapeutics for the treatment of patients with cancer in the United States. It is developing trilaciclib, an intravenous cyclin-dependent kinases (CDK) 4/6 inhibitor that is in Phase 1b/2a clinical trials for patients with small cell lung cancer, as well as Phase 2 clinical trial for patients with first-/second-/third-line metastatic triple-negative breast cancer; G1T38, an oral CDK4/6 inhibitor that is Phase 1b/2a clinical trials for the treatment of breast cancer; and G1T48, an oral selective estrogen receptor degrader, which is in preclinical development.

Featured Article: Risk Tolerance and Your Investment Decisions

Analyst Recommendations for G1 Therapeutics (NASDAQ:GTHX)

Receive News & Ratings for G1 Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for G1 Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.


Leave a Reply